{"id":"br1018a","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BR1018A is being developed by Boryung Pharmaceutical as an immunooncology agent in Phase 3 clinical trials. The specific molecular mechanism and target remain proprietary and not fully disclosed in public literature, though the company's pipeline suggests focus on checkpoint inhibition or related immunotherapy approaches.","oneSentence":"BR1018A is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:23.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oncology indication (specific indication not publicly disclosed)"}]},"trialDetails":[{"nctId":"NCT06165250","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2024-04-17","conditions":"Essential Hypertension, Primary Hypercholesterolemia","enrollment":156},{"nctId":"NCT06889012","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-05-07","conditions":"Essential Hypertension, Primary Hypercholesterolemia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BR1018A","genericName":"BR1018A","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BR1018A is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity. Used for Oncology indication (specific indication not publicly disclosed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}